Research
Hormonal
SGLT1-mediated glucose uptake is the primary mechanism for early glucose-stimulated GLP-1 and GIP secretion, whereas metabolism-dependent pathways play a lesser role in peak early secretion.
Understanding that your gut senses glucose directly via transporters helps explain why whole foods trigger satiety hormones better than isolated sugars or sweeteners.
GoodSupportsHIGH confidence
The mechanism for which there is the most support is Na+-coupled glucose uptake via the sodium/glucose cotransporter member 1 (SGLT1)... metabolism-dependent pathways are not thought to be responsible for peak GLP1 and GIP concentrations measured early after an oral glucose load
Why this rating
Supported by multiple studies including knockout mice and pharmacological inhibition.
Source
Gut chemosensing mechanisms
Arianna Psichas et al. · Journal of Clinical Investigation · 2015
DOI 10.1172/jci76309
narrative_reviewCited 237×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Ingestion of carbohydrates, proteins, and lipids stimulates enteroendocrine cells (EECs) to secrete gut hormones (GLP-1, GIP, CCK, PYY) via specific nutrient-sensing receptors and transporters, which modulates glucose homeostasis, appetite, and gastrointestinal motility.Good
- Bariatric surgery (specifically gastric bypass) leads to elevated levels of GLP-1 and PYY, which are linked to enhanced delivery of nutrients to the distal intestine and underlie beneficial outcomes on weight loss and glycemia.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →